Document:

EX-10.2

 EXHIBIT 10.2

Performance Share Plan (“Plan”)

Performance Period January 1, 2010 — December 31, 2012

	I.	 	Purpose of the Program

The purpose of the Program is to align Boston Scientific’s executive compensation
program with the interests of shareholders and to reinforce the concept of pay for
performance by comparing the Total Shareholder Return (“TSR”) of shares of Boston Scientific
Corporation Common Stock (the “Common Stock”) to the TSR of companies included in the S&P
500 Healthcare Index over a three-year period beginning on January 1, 2010.

The Program shall be administered under the Boston Scientific Corporation 2003 Long-Term
Incentive Plan (the “2003 LTIP”). Defined terms not explicitly defined in this Program
document but defined in the 2003 LTIP shall have the same meaning as in the 2003 LTIP. For
covered employees, the 2010 Plan is established under section 4.a.(9) of the Boston
Scientific Corporation 2003 Long-Term Incentive Plan and is intended to qualify for the
performance-based compensation exception under Section 162(m) of the Internal Revenue Code
(“Code”).

Boston Scientific must achieve performance greater than the median TSR of the S&P 500
Healthcare Index for eligible executives to earn the target award under the Program (as set
forth in Section III below).

	II.	 	Eligible Participants

The Program covers members of the Executive and Operating Committees on the date that
awards are granted under the Program.

The Executive Compensation and Human Resources Committee of the Board of Directors (the
“Committee”) may review Program eligibility criteria for participants in the Program from
time to time and may revise such criteria at any time, even within a Program year, with or
without notice and within its sole discretion.

III. Performance Share Units

The performance share units granted under the Program (the “Performance Share Units”)
shall vest based on the TSR of the Common Stock relative to the TSR of companies in the S&P
500 Healthcare Index. The Common Stock underlying the Performance Share Units awarded under
the Program will be granted under the Boston Scientific 2003 LTIP.

The TSR for Boston Scientific and all companies in the S&P 500 Healthcare Index will be
measured in three annual Performance Cycles (as defined below) over a three-year period
beginning January 1, 2010 and ending on December 31, 2012 (the “Performance Period”).

The final TSR calculation for determination of Performance Share Units that will vest will
be the simple average of the TSR as measured based on each of the three annual Performance
Cycles.

The Performance Share Units will pay out in shares of Common Stock in a range of 0% to 260%
of the target number of Performance Share Units awarded to the participant as follows:

	 	 	 	 	 	 	 	 	 
	 	 	TSR Performance	 	 	 	 
	 	 	Percentile Rank	 	Units Vesting	 	 
	 	 	100th Percentile

	 	 	260	%	 	             
	 	 	95th Percentile

	 	 	240	%	 	

	 	 	80th Percentile

	 	 	150	%	 	

	              
	 	55th Percentile

	 	 	100	%	 	

	 	 	30th Percentile

	 	 	50	%	 	

	 	 	Below 30th Percentile

	 	 	0	%	 	

The Performance Share Units will pay out linearly between each set of data points.

Following the end of the Performance Period, the Committee shall determine the number of
            shares of Common Stock earned, which determination shall be final and binding. Shares of
Common Stock earned will be delivered or otherwise made available to the participant no
later than March 15, 2013.

	IV.	 	Total Shareholder Return

The TSR for Boston Scientific and each company in the S&P 500 Healthcare Index shall
include any cash dividends paid during the Performance Period and shall be determined as
follows:

Total Shareholder Return for each Performance Cycle =

(Change in Stock Price + Dividends Paid) / Beginning Stock Price

Total Shareholder Return for the three-year Performance Period =

Results of (Performance Cycle 1 + Performance Cycle 2 + Performance Cycle 3) / 3

“Beginning Stock Price” means the daily average closing price as quoted on the New York
Stock Exchange or the NASDAQ Global Select Market, as applicable, of one (1) share of common
stock for the two calendar months prior to the beginning of each Performance Cycle.

“Change in Stock Price” means the difference between the Beginning Stock Price and the
Ending Stock Price.

“Dividends Paid” means the total of all cash dividends paid on one (1) share of stock during
the applicable Performance Cycle.

“Ending Stock Price” means the daily average closing price as quoted on the New York Stock
Exchange or the NASDAQ Global Select Market, as applicable, of one (1) share of common stock
for the last two calendar months of the Performance Cycle.

“Performance Cycle” means the annual period commencing each January 1 and ending on December
31 during the Performance Period.

“Performance Cycle 1” is the Performance Cycle during which the Beginning Stock Price is
determined as of January 1, 2010 and the Ending Stock Price is determined as of December 31,
2010.

“Performance Cycle 2” is the Performance Cycle during which the Beginning Stock Price is
determined as of January 1, 2011 and the Ending Stock Price is determined as of December 31,
2011.

“Performance Cycle 3” is the Performance Cycle during which the Beginning Stock Price is
determined as of January 1, 2012 and the Ending Stock Price is determined as of December 31,
2012.

Example: If the Beginning Stock Price for a company was $25.00 per share, and the company
paid $2.50 in dividends over the Performance Cycle, and the Ending Stock Price was $30.00
per share (thereby making the Change in Stock Price $5.00 ($30.00 minus $25.00)), then the
TSR for that company would be thirty percent (30%). The calculation is as follows: 0.30 =
($5.00 + $2.50) / $25.00

	V.	 	Calculation of Percentile Performance

Following the calculation of the TSR for the Performance Period for Boston Scientific
and each of the companies in the S&P 500 Healthcare Index, Boston Scientific and the
companies in the S&P 500 Healthcare Index will be ranked, in order of maximum to minimum,
according to their respective TSR for the Performance Period.

After this ranking, the percentile performance of Boston Scientific as compared to the other
companies in the S&P 500 Healthcare Index shall be determined by the following formula:

“P” represents the percentile performance which will be rounded, if necessary, to the
nearest whole percentile by application of regular rounding.

“N” represents the number of companies in the S&P 500 Healthcare Index, including Boston
Scientific.

“R” represents Boston Scientific’s ranking versus the other companies in the S&P 500
Healthcare Index.

Example: If Boston Scientific ranked 10th out of 54 companies, the performance
will be in the 83rd percentile.

	 	 	 
	 	 	This calculation is as follows: 0.83 = 1 – (10 – 1) / (54 – 1)

	VI.
	 	S&P 500 Healthcare Index

The companies currently included in the S&P 500 Healthcare Index can be found in
Appendix A attached hereto.

If two companies in the S&P 500 Healthcare Index merge, the surviving company shall remain
in the S&P 500 Healthcare Index.

If a company in the S&P 500 Healthcare Index merges with, or is acquired by, a company that
is not in the S&P 500 Healthcare Index, and the company in the S&P 500 Healthcare Index is
the surviving company, then the surviving company shall be included in the S&P 500
Healthcare Index.

If a company in the S&P 500 Healthcare Index merges with, or is acquired by, a company that
is not in the S&P 500 Healthcare Index, and the company in the S&P 500 Healthcare Index is
not the surviving company or the surviving company is no longer publicly traded, then the
surviving company shall not be included in the S&P 500 Healthcare Index.

Notwithstanding the foregoing, if a company in the S&P 500 Healthcare Index ceases to be listed in
the Healthcare Sector under the Standard & Poor’s Global Industry Classification Standard (GICS) at
anytime during the Performance Period (including after a merger, acquisition or other business
transaction described above), then it shall not be included in the S&P 500 Healthcare Index.

	VII.	 	Payment Criteria

A participant must be employed by Boston Scientific on December 31, 2012 to be eligible
to receive the full award under the Program. Except as set forth below with respect to a
Change in Control or termination of employment as a result of Retirement, death, or
Disability, no Performance Share Units shall vest prior to December 31, 2012.Participants on
military, sick or other bona fide leave of absence on December 31, 2012 will not be deemed
to have terminated employment with Boston Scientific if such absence does not exceed 180
days or, if longer, if the participant retains the right by statute or by contract to
return to employment with Boston Scientific.

If a participant’s employment with Boston Scientific terminates before the end of the
Performance Period, any unvested Performance Share Units shall be forfeited on the effective
date of the termination of employment, except in connection with Retirement, death,
Disability or upon a Change in Control as outlined below.

Upon a Change in Control or if a participant’s employment terminates due to Retirement,
death, or Disability after the end of Performance Cycle 1 (December 31, 2010) but prior to
the end of the Performance Period, the Performance Share Units shall remain outstanding and
            shares of Common Stock shall be issued on a prorated basis in accordance with Section III
but using the the date of the participant’s termination of employment (as described below).
The number of prorated shares to be issued to the participant, if any, will be approved by
the Committee at its next regular meeting.

The number of shares to be issued on a prorated basis shall be determined as follows: (#
Performance Share Units awarded) * ((# of months worked during the Performance Period,
rounded to nearest whole month) / 36). This result will be multiplied by either the
Performance Cycle 1 percentile performance funding amount (as calculated according to the
chart in Section III) or the average of the Performance Cycle 1 and Performance
Cycle 2 percentile performance funding amount (as calculated according to the chart in
Section III), depending on the date of the Change in Control or the date participant’s
employment is terminated due to Retirement, death or Disability.

	VIII.	 	Termination, Suspension or Modification and Interpretation of the Program

The Committee has sole authority over administration and interpretation of the Program
and retains its right to exercise discretion as it sees fit. The Committee may terminate,
suspend or modify and if suspended, may reinstate with or without modification all or part
of the Program at any time, with or without notice to the participant. The Committee
reserves the exclusive right to determine eligibility to participate in this Program and to
interpret all applicable terms and conditions, including eligibility criteria.

IX. Other

This document sets forth the terms of the Program and is not intended to be a contract
or employment agreement between the participant and Boston Scientific. As applicable, it is
understood that both the participant and Boston Scientific have the right to terminate the
participant’s employment with Boston Scientific at any time, with or without cause and with
or without notice, in acknowledgement of the fact that their employment relationship is “at
will.”EX-10.3

EXHIBIT 10.3

Form of Executive Committee

Change in Control Agreement

(Date)

[Name of Executive]

[Address of Executive]

Re: Change in Control Agreement

Dear [Name of Executive]:

Boston Scientific Corporation (the “Company”) considers it essential to the best interests of
its stockholders to foster the continuous employment of key management personnel. Further, the
Board of Directors of the Company (the “Board”) recognizes that the possibility of a change in
control exists, and that such possibility, and the uncertainty and questions that it may raise
among management, may result in the departure or distraction of management personnel to the
detriment of the Company and its stockholders.

The Board has determined that appropriate steps should be taken to reinforce and encourage the
continued attention and dedication of members of the management of the Company, including yourself,
to their assigned duties without distraction in the face of potentially disturbing circumstances
arising from any possible change in control of the Company. In connection with (and as an
additional inducement for) entering into this letter agreement (the “Agreement”) in substitution
for and termination of your current Retention Agreement, dated as of       , 200       (the “Retention
Agreement”), you will be granted a nonqualified stock option award by the Company having a value of
$15,000, and an exercise price equal to the closing price of Company common stock, as of the date
that such award is granted.

In order to induce you to remain in the employ of the Company, the Company agrees that you
shall receive the severance benefits set forth in this Agreement in the event your employment with
the Company is terminated subsequent to a Change in Control (as defined herein) under the
circumstances described below.

1. Term of the Agreement. Sections 2, 3, 4, 5 and 6 of this Agreement shall only be
applicable if a Change in Control occurs during the period beginning on [ ], 2009 (the “Effective
Date”) and ending on the earlier of the (i) third anniversary of the Effective Date and (ii)
termination of your employment with the Company for any reason prior to a Change in Control (the
“Term”). If a Change in Control does not occur during the Term, this Agreement will automatically
terminate at the end of the Term.

2. Termination Following a Change in Control. If a Change in Control occurs at any time
during the Term, you will be entitled to the benefits provided in Section 3 hereof upon the
subsequent termination of your employment by the Company without Cause (as defined herein) or by
you for Good Reason (as defined herein) during the two-year period following such Change in Control
(the “Covered Period”). Any purported termination of your employment by the Company or by you
shall be communicated by a Notice of Termination to the other party hereto in accordance with
Section 8 hereof. For purposes of this Agreement, (i) references to termination of employment mean
a “separation from service” (as defined in Section 1.409A-1(h) of the Treasury Regulations) from
the Company, and (ii) a “Notice of Termination” shall mean a written notice which shall indicate
the specific termination provision or provisions in this Agreement relied upon and shall set forth
in general terms the facts and circumstances claimed to provide a basis for termination of your
employment under the provision so indicated.

3. Compensation Upon Termination.

(a) Severance Benefits. If your employment by the Company shall be terminated during
the Covered Period by the Company without Cause or by you for Good Reason, then you shall be
entitled to the following benefits:

(i) Severance Payments.

(1) Amount of Payment. The Company shall pay you in cash the full amount of any
earned but unpaid base salary through the Date of Termination at the rate in effect at the
time of the Notice of Termination, plus a cash payment for all unused vacation time which
you may have accrued as of the Date of Termination. The Company shall also pay you in cash
a pro rata portion of the annual bonus for the year in which your employment terminates,
calculated on the basis of your target bonus for that year and on the assumption that all
performance targets have been or will be achieved. In addition, the Company shall pay you
in a cash lump sum, an amount (the “Severance Payment”) equal to three times the sum of (A)
your base salary on the Termination Date (without giving effect to any salary reductions
which satisfy the definition of “Good Reason”), (B) the greater of (x) the most recent
bonus paid to you (which shall be deemed to be the sum of (I) the annual cash bonus amount
most recently paid to you and (II) the grant date fair value of any equity awards granted
to you in lieu of annual bonus compensation within the immediately preceding year) and (y)
your target bonus in effect for the year in which the Change in Control occurred
(calculated assuming that all performance targets have been or will be achieved) and (C)
$25,000. The Severance Payment shall be in lieu of any other severance payments which you
are entitled to receive under any other severance pay plan or arrangement sponsored by the
Company or any of its subsidiaries.

(2) Timing of Payment. Subject to Section 3(b), the Company shall pay the amounts
due to you under this Section 3(a)(i) on the 60th day following the Date of
Termination, provided that you execute, and do not revoke, a Release Agreement in the form
attached as Exhibit A hereto.

(ii) Benefit Continuation. Subject to your compliance with the
non-solicitation and confidentiality provisions described in Section 6, you and your
eligible dependents shall continue to be eligible to participate during the Benefit
Continuation Period (as hereinafter defined) in the medical, dental, health, life and other
welfare benefit plans and arrangements applicable to you immediately prior to your
termination of employment on the same terms and conditions in effect for you and your
dependents immediately prior to such termination; provided that the provision of such
benefits in each calendar year during the Benefit Continuation Period does not affect the
provision of such benefits in any other calendar year during the Benefit Continuation
Period. For purposes of the previous sentence, “Benefit Continuation Period” means the
period beginning on the Date of Termination and ending on the earlier to occur of (i) the
third anniversary of the Date of Termination and (ii) the date that you and your dependents
are eligible for coverage under the plans of a subsequent employer which provide
substantially equivalent or greater benefits to you and your dependents. The right to
participate in the benefit plans under this Section 3(a)(ii) is not subject to liquidation
or exchange for any other benefit;

(iii) Legal Fees and Expenses. The Company shall also pay you in cash all
legal fees and expenses, if any, incurred by you in contesting or disputing any such
termination or in seeking to obtain or enforce any right or benefit provided by this
Agreement if such expenses are incurred on or prior to the December 31 of the second
calendar year following the calendar year in which the Date of Termination occurs, such
payment(s) to be made on or before the December 31 of the third calendar year following the
calendar year(s) in which the Date of Termination occurs; provided, however, that
the amount of the payments and reimbursements under this Section 3(a)(iii) shall not exceed
$100,000; and provided, further, that no such legal fees or expenses shall be reimbursed if
it is determined by the applicable arbitral panel or other tribunal that your claim is
entirely without merit. Furthermore, nothing shall prohibit the arbitral panel or other
tribunal from awarding legal fees in excess of $100,000 if, in the interests of fairness
and equity, the arbitral panel or other tribunal deems such award appropriate. The right
to receive payments and reimbursements under this Section 3(a)(iii) is not subject to
liquidation or exchange for any other benefit.

(b) Specified Employee. Notwithstanding anything to the contrary in this Agreement, if you
are a “specified employee” as hereinafter defined at the time of the Date of Termination, any and
all amounts payable in connection with your termination of employment (including amounts payable
under this Section 3) that constitute deferred compensation subject to Section 409A of the Code, as
determined by the Executive Compensation and Human Resources Committee (the “Committee”) in its
sole discretion, and that would (but for this sentence) be payable within six months following the
Date of Termination, shall instead be paid on the date that follows the Date of Termination by six
months and one day (the “Specified Employee Payment Date”). The provision of benefits pursuant to
Section 3(a)(ii) that constitute deferred compensation under Section 409A of the Code will not be
provided in-kind during the first six months following the Date of Termination, but rather will be
continued by your payment of any applicable premiums for which you will be reimbursed on the
Specified Employee Payment Date. The provision of in-kind benefits will commence on the Specified
Employee Payment Date in accordance with Section 3(a)(ii). For purposes of this Agreement, the
term “specified employee” means an individual who is determined by the Committee to be a specified
employee as defined in Section 409A(a)(2)(B)(i) of the Code. The Committee may, but need not,
elect in writing, subject to the applicable limitations under Section 409A of the Code, any of the
special elective rules prescribed in Section 1.409A-1(i) of the Treasury Regulations for purposes
of determining “specified employee” status. Any such written election shall be deemed part of this
Agreement.

(c) No Mitigation. You shall not be required to mitigate the amount of any payment or
benefit provided for in this Section 3 by seeking other employment or otherwise.

(d) Reduction of Severance Payments if Reduction Would Result in Greater After-Tax Amount.
Notwithstanding anything herein to the contrary, in the event that you receive any payments or
distributions, whether payable or distributed or distributable pursuant to the terms of this
Agreement or otherwise, that constitute “parachute payments” within the meaning of Section 280G of
the Code, and the net after-tax amount of the parachute payment, including any applicable excise
taxes under Section 4999 of the Code, is less than the net after-tax amount if your aggregate
payment were three times your “base amount” (as defined in Section 280G(b)(3) of the Code) less
$1.00, then the Severance Payments shall be sufficiently reduced to ensure that the aggregate value
of the amounts constituting the parachute payment will equal three times your base amount, less
$1.00. The determinations to be made with respect to this Section 3(d) shall be made by an
Accounting Firm.

4. Equity Incentive Awards.

(a) Options. All outstanding options granted to you under the Company’s equity incentive plans
shall vest and become exercisable if your employment is terminated without Cause or you resign your
employment for Good Reason during the Covered Period; provided, however, that if the surviving or
acquiring entity does not provide for the substitution or assumption of the outstanding options,
your outstanding options shall immediately become exercisable upon a Change in Control. If no such
termination or resignation occurs during the Covered Period and the outstanding options are
substituted or assumed, your outstanding options shall continue to vest pursuant to the terms of
the Company’s equity incentive plans or applicable award agreement.

(b) Restricted Stock and Deferred Stock Unit Awards. All restricted stock and deferred stock
unit awards granted to you under the Company’s equity incentive plans shall become free from
restriction if your employment is terminated without Cause or you resign your employment for Good
Reason during the Covered Period; provided, however, that if the surviving or acquiring entity does
not provide for the substitution or assumption of outstanding restricted stock or deferred stock
unit awards, your outstanding restricted stock and deferred stock unit awards shall immediately
become free from restriction upon a Change in Control. If no such termination or resignation
occurs during the Covered Period and the outstanding restricted stock or deferred stock unit awards
are substituted or assumed, your restricted stock and deferred stock unit awards shall continue to
vest in accordance with the terms of the Company’s equity incentive plans or applicable award
agreement.

	 	5.	 	Successors; Binding Agreement.

(a) Assumption By Successor. The Company will require any successor (whether direct
or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the
business or assets of the Company to expressly assume and agree to perform this Agreement in the
same manner and to the same extent that the Company would be required to perform it if no such
succession had taken place. Failure of the Company to obtain such assumption and agreement prior
to the effectiveness of any such succession shall be a breach of this Agreement and shall entitle
you to compensation from the Company in the same amount and on the same terms as you would be
entitled hereunder if you had terminated your employment for Good Reason following a Change in
Control, except that for purposes of implementing the foregoing, the date on which any such
succession becomes effective shall be deemed the Date of Termination. As used in this Agreement,
“the Company” shall mean the Company as hereinbefore defined and any successor to its business or
assets which assumes and agrees to perform this Agreement by operation of law, by agreement or
otherwise.

(b) Enforceability By Beneficiaries. This Agreement shall inure to the benefit of and
be enforceable by your personal or legal representatives, executors, administrators, successors,
heirs, distributees, devisees and legatees. If you should die while any amount would still be
payable to you hereunder if you had continued to live, all such amounts, unless otherwise provided
herein, shall be paid in accordance with the terms of this Agreement to your devisee, legatee or
other designee or, if there is no such designee, to your estate.

6. Nonsolicitation; Confidentiality.

(a) Nonsolicitation. For two years following your Date of Termination, you shall not,
without the prior written consent of the Company, directly or indirectly, as a sole proprietor,
member of a partnership, stockholder or investor, officer or director of a corporation, or as an
employee, associate, consultant, independent contractor or agent of any person, partnership,
corporation or other business organization or entity other than the Company: (i) solicit or
endeavor to entice away from the Company or any of its affiliates or subsidiaries, any person or
entity who is, or, during the then most recent 12-month period, was, employed by, or had served as
an agent or key consultant of, the Company or any of its subsidiaries, or (ii) solicit or endeavor
to entice away from the Company or any of its subsidiaries any person or entity who is, or was
within the then most recent 12-month period, a customer or client (or reasonably anticipated (to
your general knowledge or the public’s general knowledge) to become a customer or client) of the
Company or any of its subsidiaries.

(b) Confidentiality. On and after the date of this Agreement, you will not, except in
the performance of your obligations to the Company hereunder or as may otherwise be approved in
advance by the Board, directly or indirectly, disclose or use (except for the direct benefit of the
Company) any confidential information that you may learn or have learned by reason of your
association with the Company, any customer or client of the Company or any of their respective
subsidiaries and affiliates. The term “confidential information” includes all data, analyses,
reports, interpretations, forecasts, documents and information in any form concerning or otherwise
reflecting information and concerning the Company and its affairs, including, without limitation,
with respect to clients, products, policies, procedures, methodologies, trade secrets and other
intellectual property, systems, personnel, confidential reports, technical information, financial
information, business transactions, business plans, prospects or opportunities, but shall exclude
any portion of such information that (i) was acquired by you prior to your employment by, or other
association with, the Company or any affiliated or predecessor entity, (ii) is or becomes generally
available to the public or is generally known in the industry or industries in which the Company or
any customer or client of the Company operates, in each case other than as a result of disclosure
by you in violation of this Section 6 or (iii) you are required to disclose under any applicable
laws, regulations or directives of any government agency, tribunal or authority having jurisdiction
in the matter or under subpoena or other process of law. As used in this Section 6, an “affiliate”
of a person or entity is a person or entity in control of, controlled by, or in common control
with, such first person or entity.

7. Definitions. For purposes of this Agreement, the following capitalized words shall
have the meanings set forth below:

“Accounting Firm” shall mean the then-current independent auditors of the Company or, if such
firm is unable or unwilling to perform such calculations, such other national accounting firm as
shall be designated by agreement between you and the Company.

“Cause” shall mean the willful engaging by you in criminal or fraudulent acts or gross
misconduct that is demonstrably and materially injurious to the Company, monetarily or otherwise.
No act or failure to act on your part shall be deemed “willful” unless done, or omitted to be done,
by you not in good faith and without reasonable belief that your action or omission was in the best
interest of the Company. Notwithstanding the foregoing, you shall not be deemed to have been
terminated for Cause unless and until there shall have been delivered to you a copy of a resolution
duly adopted by the affirmative vote of not less than three quarters of the entire membership of
the Board at a meeting of the Board called and held for such purpose (after reasonable notice to
you and an opportunity for you, together with your counsel, to be heard before the Board), finding
that in the good faith opinion of the Board you were guilty of conduct set forth above in the first
sentence of this subsection and specifying the particulars thereof in detail.

“Change in Control” shall mean the happening of any of the following:

(a) The acquisition, other than from the Company, by any individual, entity or group
(within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”)) of beneficial ownership (within the meaning of Rule 13d-3
promulgated under the Exchange Act) of 20% or more of either (i) the then outstanding
            shares of common stock of the Company (the “Outstanding Company Common Stock”) or (ii) the
combined voting power of the then outstanding voting securities of the Company entitled to
vote generally in the election of directors (the “Company Voting Securities”); provided,
however, that any acquisition by (x) any non-corporate shareholder of the Company who owned
10% or more of the Outstanding Company Common Stock as of the effective date of the initial
registration of an offering of Stock under the Securities Act of 1933, (y) the Company or
any of its affiliates or subsidiaries, or any employee benefit plan (or related trust)
sponsored or maintained by the Company or any of its subsidiaries or (z) any corporation
with respect to which, following such acquisition, more than 50% of, respectively, the then
outstanding shares of common stock of such corporation and combined voting power of the
then outstanding voting securities of such corporation entitled to vote generally in the
election of directors is then beneficially owned, directly or indirectly, by all or
substantially all of the individuals and entities who were the beneficial owners,
respectively, of the Outstanding Company Common Stock and Company Voting Securities
immediately prior to such acquisition in substantially the same proportion as their
ownership, immediately prior to such acquisition, of the Outstanding Common Stock and
Company Voting Securities, as the case may be, shall not constitute a Change in Control of
the Company; or

(b) Individuals who, as of the Effective Date, constitute the Board (the “Incumbent
Board”) cease for any reason to constitute at least a majority of the Board, provided that
any individual becoming a director subsequent to such effective date whose election or
nomination for election by the Company’s shareholders, was approved by a vote of at least a
majority of the directors then comprising the Incumbent Board shall be considered as though
such individual were a member of the Incumbent Board, but excluding, for this purpose, any
such individual whose initial assumption of office is in connection with an actual or
threatened election contest relating to the election of the Directors of the Company (as
such terms are used in Rule 14a-11 of Regulation 14A promulgated under the Exchange Act);
or

(c) Consummation of a reorganization, merger, consolidation or similar transaction
involving the Company (a “Business Combination”), in each case, with respect to which all
or substantially all of the individuals and entities who were the respective beneficial
owners of the Outstanding Company Common Stock and Company Voting Securities immediately
prior to such Business Combination do not own beneficially, directly or indirectly, more
than 50% of, respectively, the then outstanding shares of common stock and the combined
voting power of the then outstanding voting securities entitled to vote generally in the
election of directors, as the case may be, of the corporation resulting from such Business
Combination in substantially the same proportion as their ownership immediately prior to
such Business Combination of the Outstanding Company Common Stock and Company Voting
Securities, as the case may be; or

(d) A complete liquidation or dissolution of the Company or a sale or other
disposition of all or substantially all of the assets of the Company other than to a
corporation with respect to which, following such sale or disposition, more than 50% of,
respectively, the then outstanding shares of common stock and the combined voting power of
the then outstanding voting securities entitled to vote generally in the election of
directions is then owned beneficially, directly or indirectly, by all or substantially all
of the individuals and entities who were the beneficial owners, respectively, of the
Outstanding Company Common Stock and Company Voting Securities immediately prior to such
sale or disposition in substantially the same proportion as their ownership of the
Outstanding Company Common Stock and Company Voting Securities, as the case may be,
immediately prior to such sale or disposition.

Notwithstanding the foregoing, with respect to any amounts payable under this Agreement
that are subject to Section 409A of the Code where the payment is to be accelerated in
connection with the Change in Control, no event(s) set forth above shall constitute a
Change in Control for purposes of the Agreement unless such event(s) also constitutes a
“change in the ownership”, “change in the effective control” or a “change in the ownership
of a substantial portion of the assets” of the Company as defined under Section 409A of the
Code.

“Code” shall mean the Internal Revenue Code of 1986, as amended, and any successor provisions
thereto.

“Date of Termination” shall be the date on which you experience a “separation from service”
(as defined in Section 1.409A-1(h) of the Treasury Regulations) from the Company upon the
termination of your employment by the Company without Cause or by you for Good Reason. Such Date
of Termination shall be the date specified in the Notice of Termination (which, in the case of a
termination by the Company without Cause shall not be less than 30 days, and in the case of a
resignation by you for Good Reason shall not be less than 30 nor more than 60 days from the date
such Notice of Termination is given); provided, that if within 30 days after any Notice of
Termination is given the party receiving such Notice of Termination notifies the other party that a
dispute exists concerning the termination, the Date of Termination shall be the date on which the
dispute is finally determined, either by mutual written agreement of the parties, by a binding
arbitration award, or by a final judgment, order or decree of a court of competent jurisdiction
(which is not appealable or the time for appeal therefrom having expired and no appeal having been
perfected); provided, further, that the Date of Termination shall be extended by a notice of
dispute only if such notice is given in good faith and the party giving such notice pursues the
resolution of such dispute with reasonable diligence. Notwithstanding the pendency of any such
dispute, the Company will continue to pay you your full compensation in effect when the notice
giving rise to the dispute was given, continue you as a participant in all compensation, benefit,
and insurance plans and perquisites in which you were participating when the notice giving rise to
the dispute was given and the Company will not require that you provide any services to the
Company, until the dispute is finally resolved in accordance with this Subsection. Amounts paid
under this Subsection are in addition to all other amounts due under this Agreement and shall not
be offset against or reduce any other amounts due under this Agreement.

“Good Reason” shall mean, without your express written consent, any of the following:

(a) The assignment to you of any duties inconsistent with your status as an executive
officer of the Company or an adverse alteration in the nature or status of your duties,
responsibilities, authorities, reporting relationships or titles from those in effect
immediately prior to the Change in Control;

(b) A reduction by the Company in your annual base salary as in effect on the date
hereof or as the same may be increased from time to time; a failure by the Company to
increase your salary at a rate commensurate with that of other key executives of the
Company; a reduction in your annual bonus (expressed as a percentage of base salary) below
the target in effect for you immediately prior to the Change in Control; or any adverse
change in your long-term incentive opportunities in comparison to those in effect prior to
the Change in Control;

(c) The relocation of your principal place of work to any location (other than the
Company’s main headquarters) that is more than 50 miles from your principal place of work
on the date of the Change in Control (except for required travel on the Company’s business
to an extent substantially consistent with your customary business travel obligations in
the ordinary course of business prior to the Change in Control), or in the event you
consent to any such relocation, the Company’s failure to provide you with all of the
benefits of the Company’s relocation policy as in operation immediately prior to the Change
in Control;

(d) The failure by the Company to continue in effect any compensation plan, including,
but not limited to, incentive or deferred compensation plans, in which you participate or
the failure by the Company to continue your participation therein on at least as favorable
a basis, both in terms of the amount of benefits provided and the level of your
participation relative to other participants, as existed at the time of the Change in
Control;

(e) The failure by the Company to continue to provide you with benefits at least as
favorable as those enjoyed by you under any of the Company’s retirement, life insurance,
medical, health and accident, disability or savings plans in which you were participating
at the time of the Change in Control; the taking of any action by the Company that would
directly or indirectly reduce any of such benefits or deprive you of any perquisite enjoyed
by you at the time of the Change in Control including without limitation, the use of a car,
secretary, office space, telephones, expense reimbursement and club dues; or the failure by
the Company to provide you with the number of paid vacation days to which you are entitled
on the basis of years of service with the Company in accordance with the Company’s normal
vacation policy in effect at the time of the Change in Control;

(f) The failure of the Company to pay you any amounts of salary, bonus, benefits or
expense reimbursement then owed to you or the failure of the Company to adhere to its
payroll and other compensation schedules in place just prior to the Change in Control,
including, but not limited to, the failure to pay any installment of deferred compensation
under any deferred compensation plan or program of the Company, within seven (7) days of
the date the compensation is due;

(g) The failure of the Company to obtain a satisfactory agreement from any successor
to assume and agree to perform this Agreement, as contemplated in Section 5 hereof or, if
the business of the Company for which your services are principally performed is sold at
any time after a Change in Control, the purchaser of such business shall fail to agree to
provide you with the same or a comparable position, duties, compensation and benefits (as
described in subsections (d) and (e) above) as provided to you by the Company immediately
prior to the Change in Control; or

(h) Any purported termination of your employment which is not effected pursuant to a
Notice of Termination satisfying the requirements of Section 2 (and, if applicable, the
requirements set out in the definition of “Cause” above); for purposes of this Agreement,
no such purported termination shall be effective.

Your right to terminate your employment for Good Reason will not be affected by your
incapacity due to physical or mental illness. Your continued employment will not constitute a
waiver of rights with respect to any act or failure to act that constitutes Good Reason.

“Payment” means (i) any amount due or paid to you under this Agreement, (ii) any amount that
is due or paid to you under any plan, program or arrangement of the Company and its subsidiaries,
and (iii) any amount or benefit that is due or payable to you under this Agreement or under any
plan, program or arrangement of the Company and its subsidiaries not otherwise covered under clause
(i) or (ii) hereof which must reasonably be taken into account under Section 280G of the Code and
the Regulations in determining the amount of the “parachute payments” received by you, including,
without limitation, any amounts which must be taken into account under the Code and Regulations as
a result of (x) the acceleration of the vesting of Options, restricted stock or other equity
awards, (y) the acceleration of the time at which any payment or benefit is receivable by you or
(z) any contingent severance or other amounts that are payable to you.

“Regulations” shall mean the proposed, temporary and final regulations under Section 280G of
the Code or any successor provision thereto.

“Taxes” shall mean the federal, state and local income taxes to which you are subject at the
time of determination, calculated on the basis of the highest marginal rates then in effect, plus
any additional payroll or withholding taxes to which you are then subject.

8. Notice. For the purpose of this Agreement, notices and all other communications
provided for in the Agreement shall be in writing and shall be deemed to have been duly given when
delivered or mailed by United States registered mail, return receipt requested, postage prepaid,
addressed to, the Chief Executive Officer or the General Counsel, Boston Scientific Corporation,
One Boston Scientific Place, Natick, MA 01760-1537, or to you at the address set forth on the
signature page of this Agreement or to such other address as either party may have furnished to the
other in writing in accordance herewith, except that notice of change of address shall be effective
only upon receipt.

9. Miscellaneous. No provision of this Agreement may be modified, waived or
discharged unless such waiver, modification or discharge is agreed to in writing. No waiver by
either party hereto at any time of any breach by the other party hereto of, or compliance with, any
condition or provision of this Agreement to be performed by such other party shall be deemed a
waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent
time. No agreements or representations, oral or otherwise, express or implied, with respect to the
subject matter hereof have been made by either party that are not expressly set forth in this
Agreement and this Agreement shall supersede all prior agreements, negotiations, correspondence,
undertakings and communications of the parties, oral or written, including, without limitation, the
Retention Agreement, with respect to the subject matter hereof. The validity, interpretation,
construction and performance of this Agreement shall be governed by the laws of the Commonwealth of
Massachusetts.

10. Validity. The invalidity or unenforceability of any provision of this Agreement
shall not affect the validity or enforceability of any other provision of this Agreement, which
shall remain in full force and effect.

11. Counterparts. This Agreement may be executed in several counterparts, each of
which shall be deemed to be an original but all of which together will constitute one and the same
instrument.

12. Arbitration. Any dispute or controversy arising under or in connection with this
Agreement shall be settled exclusively by arbitration in Boston in accordance with the rules of the
American Arbitration Association then in effect. Judgment may be entered on the arbitrator’s award
in any court having jurisdiction; provided, however, that you shall be entitled to seek specific
performance of your right to be paid until the Date of Termination during the pendency of any
dispute or controversy arising under or in connection with this Agreement. You shall be entitled
to legal fees and expenses relating to an arbitration in accordance with the terms of Section
3(a)(iii) of this Agreement.

13. No Contract of Employment. Nothing in this Agreement shall be construed as giving
you any right to be retained in the employ of the Company.

14. Headings. The headings contained in this Agreement are intended solely for
convenience and shall not affect the rights of the parties to this Agreement.

If this letter sets forth our agreement on the subject matter hereof, kindly sign and return to the
Company the enclosed copy of this letter which will then constitute our agreement on this subject.

Sincerely,

BOSTON SCIENTIFIC CORPORATION

By

J. Raymond Elliott

President and Chief Executive Officer

The foregoing is accepted and agreed to.

[Name of Executive]

1

EXHIBIT A

RELEASE AGREEMENT

I am a party to an agreement with Boston Scientific Corporation (the “Company”), dated     ,       ,
20      , entitled Change in Control Agreement (the “Change in Control Agreement”). I acknowledge that
this is the Release Agreement required by the Company pursuant to Section 3(a)(i)(2) of the Change
in Control Agreement as a condition of my eligibility for the Severance Payment (as defined in the
Change in Control Agreement) (the “Consideration”).

1. Release of Claims. In consideration of and in exchange for the commitment of the Company to
provide the Consideration, I, for myself, my heirs, administrators, executors and assigns agree to
release and forever discharge the Company and its subsidiaries, affiliated companies, successors
and assigns, and the current and former employees, officers, directors, shareholders (but only in
their capacity as shareholders of the Company) and agents of each of the foregoing (the “Released
Parties”), from any and all claims, agreements, obligations, injuries, damages, causes of action,
debts or liabilities (together “Claims”), including, without limitation, Claims under the Civil
Rights Act of 1866, Title VII of the Civil Rights Act of 1964, the Age Discrimination in Employment
Act of 1967 (“ADEA”), the Civil Rights Act of 1991, the Americans with Disabilities Act of 1990,
the Family and Medical Leave Act of 1993, and any other federal, state, local or foreign law, that
I may have, may have ever had or may possess in the future, whether known or unknown, against any
of the Released Parties, arising out of (i) my employent relationship with and service as an
employee, officer or director of the Company, and the termination of such relationship or service,
and (ii) any event, condition, circumstance or obligation that occurred, existed or arose on or
prior to the date hereof; provided, however, that I do not release, discharge, or waive any rights
to payments and benefits under the Change in Control Agreement that are contingent upon my
execution of this Release Agreement.

2. Consideration of Release Agreement. I understand that I have had the opportunity, in accordance
with ADEA, if I so desired, to take up to twenty-one (21) days to consider this Release Agreement.
I agree that any modifications, material or otherwise, made to this Release Agreement do not
restart or affect in any manner the original twenty-one (21) day consideration period. I further
acknowledge that I have been advised to consult with an attorney prior to executing this Release
Agreement.

3. Revocation Period. I understand that, in accordance with ADEA, I will have seven (7) days
following my signing of this Release Agreement in which to revoke this Release Agreement by a
written notice to be received by the Company’s Executive Vice President of Human Resources no later
than the end of such seven-day period. I understand that this Release Agreement shall not become
effective until the revocation period has expired.

4. Receipt of Payment. I acknowledge that I have received payment for all salary, vacation pay and
other compensation due to me based on my employment with the Company to and including the most
recent regular payroll date of the Company preceding the date of my signing the Release Agreement.

5. No Admission. I understand and agree that this Release Agreement is not to be construed as an
admission of liability by the Released Parties.

6. Miscellaneous Provisions. I agree that this Release Agreement shall be subject to Sections 8,
9, 10, 11, 12 and 14 of the Change in Control Agreement.

7. Full Review of Release Agreement. My signature below confirms that I have carefully read and
reviewed this Release Agreement. I fully understand all of its terms and conditions and have not
relied upon any other representation by the Company or the employees or agents of the Company
concerning the terms of this Release Agreement. I execute and deliver this Release Agreement
freely and voluntarily.

UNDERSTOOD, ACCEPTED AND AGREED

[INSERT NAME]

     

Name:

Date:

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}]]